Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Code of Conduct [a]
CC transcript
|
|
EyePoint Pharmaceuticals, Inc. (EYPT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/24/2023 |
4
| EW Healthcare Partners, L.P. (10% Owner) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Sold 46,778 shares
@ $14.6187, valued at
$683.8k
Sold 121,103 shares
@ $13.0543, valued at
$1.6M
|
|
| 07/12/2023 |
4
| Duker Jay S. (President and CEO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 50,000 restricted stock units
@ $0
Granted 100,000 options to buy
@ $9.11, valued at
$911k
|
|
| 07/12/2023 |
4
| Lurker Nancy (Executive Vice Chair) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 33,334 restricted stock units
@ $0
Granted 66,666 options to buy
@ $9.11, valued at
$607.3k
|
|
| 07/12/2023 |
4
| Zaderej Karen L. (Director) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Exercised 2,000 restricted stock units
@ $0 |
|
| 05/31/2023 |
4
| Liu Ye (Director) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Sold 1 shares
@ $6, valued at
$6 |
|
| 05/30/2023 |
4
| Pine Michael Craig (Chief Corp Dev.&Strat. Officer) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 15,000 options to buy
@ $5.93, valued at
$89k
Granted 7,500 restricted stock units
@ $0 |
|
| 05/30/2023 |
4
| Elston George (CFO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 45,000 options to buy
@ $5.93, valued at
$266.9k
Granted 22,500 restricted stock units
@ $0 |
|
| 05/15/2023 |
4
| Lurker Nancy (CEO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Gifted 21,250 options to buy
@ $36.3, valued at
$771.4k
Gifted 21,250 options to buy
@ $36.3, valued at
$771.4k
Gifted 65,868 options to buy
@ $26.5, valued at
$1.7M
Gifted 65,868 options to buy
@ $26.5, valued at
$1.7M
Gifted 36,000 options to buy
@ $20.4, valued at
$734.4k
Gifted 36,000 options to buy
@ $20.4, valued at
$734.4k
Gifted 8,000 options to buy
@ $17.7, valued at
$141.6k
Gifted 8,000 options to buy
@ $17.7, valued at
$141.6k
Gifted 120,206 options to buy
@ $13.13, valued at
$1.6M
Gifted 120,206 options to buy
@ $13.13, valued at
$1.6M
Gifted 59,220 options to buy
@ $12.9, valued at
$763.9k
|
|
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/10/2023 |
4
| Lurker Nancy (CEO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 450,800 options to buy
@ $3.26, valued at
$1.5M
|
|
| 01/10/2023 |
4
| Duker Jay S. (President and COO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 124,755 options to buy
@ $3.26, valued at
$406.7k
|
|
| 01/10/2023 |
4
| Elston George (CFO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 91,655 options to buy
@ $3.26, valued at
$298.8k
|
|
| 01/10/2023 |
4
| Jones David Scott (SVP & Chief Commercial Officer) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 91,655 options to buy
@ $3.26, valued at
$298.8k
|
|
| 01/10/2023 |
4
| Pine Michael Craig (Chief Corp Dev.&Strat. Officer) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 91,655 options to buy
@ $3.26, valued at
$298.8k
|
|
| 01/10/2023 |
4
| Paggiarino Dario A. (Chief Medical Officer) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 91,655 options to buy
@ $3.26, valued at
$298.8k
|
|
| 11/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/09/2022 |
4
| Duker Jay S. (COO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 65,300 options to buy
@ $9.45, valued at
$617.1k
|
|
| 07/13/2022 |
4
| Zaderej Karen L. (Director) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 6,000 restricted stock units
@ $0
Granted 22,000 options to buy
@ $8.22, valued at
$180.8k
|
|
| 06/27/2022 |
4
| ADAMIS ANTHONY P (Director) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Granted 6,000 restricted stock units
@ $0
Granted 22,000 options to buy
@ $7.54, valued at
$165.9k
|
|
| 03/15/2022 |
4
| Pine Michael Craig (Chief Corp Dev.&Strat. Officer) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Bought 1,000 shares
@ $12.21, valued at
$12.2k
|
|
| 03/02/2022 |
4
| Jones David Scott (SVP & Chief Commercial Officer) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 1,130 shares
@ $9.95, valued at
$11.2k
Exercised 4,105 restricted stock units
@ $0 |
|
| 03/02/2022 |
4
| Paggiarino Dario A. (Chief Medical Officer) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 1,294 shares
@ $9.95, valued at
$12.9k
Exercised 4,105 restricted stock units
@ $0 |
|
| 03/02/2022 |
4
| Lurker Nancy (President & CEO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Exercised 12,466 restricted stock units
@ $0 |
|
| 02/23/2022 |
4
| Lurker Nancy (President & CEO) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Exercised 13,717 restricted stock units
@ $0 |
|
| 02/11/2022 |
4
| Landis John B. (Director) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Exercised 2,500 restricted stock units
@ $0
Granted 3,000 restricted stock units
@ $0
Granted 11,000 options to buy
@ $10.13, valued at
$111.4k
|
|
| 02/11/2022 |
4
| GUYER DAVID R (Director) has filed a Form 4 on EyePoint Pharmaceuticals, Inc.|
Txns:
| Exercised 2,500 restricted stock units
@ $0
Granted 3,000 restricted stock units
@ $0
Granted 11,000 options to buy
@ $10.13, valued at
$111.4k
|
|
|
|
|